We are live on ! Find out more
MWNA

Marshall Wace North America Portfolio holdings

AUM $23.5B
1-Year Est. Return 46.46%
This Fund
S&P 500
This Quarter Est. Return
+6.83%
1 Year Est. Return
+46.46%
3 Year Est. Return
+109.4%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$18.1B
AUM Growth
+$2.29B
Cap. Flow
+$1.49B
Cap. Flow %
8.21%
Top 10 Hldgs %
14.26%
Holding
1,826
New
616
Increased
338
Reduced
371
Closed
491

Top Buys

Rank Stock Value
1
BSX icon
Boston Scientific
BSX
+$219M
2
TWX
Time Warner Inc
TWX
+$207M
3
DGX icon
Quest Diagnostics
DGX
+$161M
4
CVS icon
CVS Health
CVS
+$154M
5
PCG icon
PG&E
PCG
+$143M

Top Sells

Rank Stock Value
1
AMAT icon
Applied Materials
AMAT
+$162M
2
TXN icon
Texas Instruments
TXN
+$103M
3
AMZN icon
Amazon
AMZN
+$85.6M
4
DAL icon
Delta Air Lines
DAL
+$76M
5
NVDA icon
NVIDIA
NVDA
+$75.7M

Sector Composition

Rank Sector Weight
1 Healthcare 23.56%
2 Technology 14.21%
3 Consumer Discretionary 12.36%
4 Industrials 10.91%
5 Communication Services 9.38%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FSM icon
1301
Fortuna Silver Mines
FSM
$2.9B
$162K ﹤0.01%
31,000
-408,058
-93% -$1.84M
AROC icon
1302
Archrock
AROC
$5.84B
$143K ﹤0.01%
+13,612
New +$148K
HOV icon
1303
Hovnanian Enterprises
HOV
$789M
$138K ﹤0.01%
+1,651
New +$102K
HABT
1304
DELISTED
The Habit Restaurants, Inc. - Class A
HABT
$134K ﹤0.01%
+14,037
New +$149K
ANH
1305
DELISTED
Anworth Mortgage Asset Corporation
ANH
$132K ﹤0.01%
+24,202
New +$138K
ACTG icon
1306
Acacia Research
ACTG
$451M
$131K ﹤0.01%
32,284
-72,775
-69% -$308K
OCUL icon
1307
Ocular Therapeutix
OCUL
$1.92B
$112K ﹤0.01%
+25,133
New +$128K
AVDL
1308
DELISTED
Avadel Pharmaceuticals
AVDL
$111K ﹤0.01%
+13,517
New +$127K
TUES
1309
DELISTED
Tuesday Morning Corp
TUES
$111K ﹤0.01%
+40,392
New +$114K
SDLP
1310
DELISTED
SEADRILL PARTNERS LLC
SDLP
$111K ﹤0.01%
+3,033
New +$112K
NTRA icon
1311
Natera
NTRA
$38B
$107K ﹤0.01%
+11,949
New +$129K
SIOX
1312
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$103K ﹤0.01%
2,438
– –
ARQ icon
1313
Arq
ARQ
$90.6M
$102K ﹤0.01%
+10,537
New +$112K
INSY
1314
DELISTED
Insys Therapeutics, Inc.
INSY
$102K ﹤0.01%
+10,630
New +$69.6K
CHRS icon
1315
Coherus Oncology
CHRS
$194M
$101K ﹤0.01%
+11,512
New +$123K
ZIXI
1316
DELISTED
Zix Corporation
ZIXI
$101K ﹤0.01%
+23,156
New +$109K
KPTI icon
1317
Karyopharm Therapeutics
KPTI
$44.2M
$97K ﹤0.01%
+676
New +$109K
PFX icon
1318
PhenixFIN
PFX
$88.1M
$97K ﹤0.01%
+927
New +$106K
UIS icon
1319
Unisys
UIS
$210M
$92K ﹤0.01%
+11,243
New +$92.2K
ECOM
1320
DELISTED
CHANNELADVISOR CORPORATION
ECOM
$92K ﹤0.01%
+10,168
New +$101K
GOGL
1321
DELISTED
Golden Ocean Group
GOGL
$86K ﹤0.01%
+10,535
New +$85.3K
ELP
1322
DELISTED
Companhia Paranaense de Energia (COPEL)
ELP
$84K ﹤0.01%
+27,630
New +$85.7K
OCLR
1323
DELISTED
Oclaro Inc.
OCLR
$80K ﹤0.01%
11,903
-432,045
-97% -$3.19M
FNKO icon
1324
Funko
FNKO
$295M
$78K ﹤0.01%
+11,798
New +$91K
GNMK
1325
DELISTED
GenMark Diagnostics, Inc
GNMK
$61K ﹤0.01%
14,544
-433,110
-97% -$2.61M
51 52
53
54 55

Similar funds

TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
PAM
PFM Asset Management Harrisburg, Pennsylvania $5.36B AUM 21.04% 1-Year Est. Return
HB
Homrich & Berg Atlanta, Georgia $4.47B AUM 22.61% 1-Year Est. Return
MWA
Marshall Wace Asia Central, Hong Kong $4.23B AUM 69.9% 1-Year Est. Return
3SCA
36 South Capital Advisors London, United Kingdom $3.76B AUM
HFCIV
H&F Corporate Investors VII San Francisco, California $3.61B AUM 26.49% 1-Year Est. Return
DVC
Deer VIII & Co Larchmont, New York $3.56B AUM
NAM
NorthCoast Asset Management Greenwich, Connecticut $2.74B AUM 25.44% 1-Year Est. Return

Marshall Wace North America's Q4 2017 Portfolio in Review

As of Q4 2017, Marshall Wace North America held 1,826 positions worth $18.1B, up 14% from $15.8B the previous quarter. Its ten largest holdings account for 14% of the portfolio.

Marshall Wace North America deployed $1.49B of net new capital in Q4 2017, opening 616 new positions and adding to 338 existing holdings. Its largest new stake was Time Warner Inc: 2,188,772 shares worth $200M.

By sector, the portfolio is most concentrated in Healthcare at 24% of assets, up from 20% a quarter earlier, followed by Technology and Consumer Discretionary.

On the sell side, the largest reduction was Applied Materials, an estimated $162M trimmed.

  • Marshall Wace North America's largest Q4 2017 buy was Time Warner Inc: 2,188,772 shares worth $200M.
  • Marshall Wace North America added most to Boston Scientific in Q4 2017, an estimated $219M increase.
  • Marshall Wace North America's biggest Q4 2017 reduction was Applied Materials, cutting an estimated $162M.
  • Marshall Wace North America fully exited NVIDIA in Q4 2017, selling an estimated $75.7M.
  • Marshall Wace North America's ten largest holdings make up 14% of its $18.1B portfolio in Q4 2017.
  • Marshall Wace North America opened 616 new positions and closed 491 in Q4 2017.
  • Marshall Wace North America's portfolio value rose 14% quarter-over-quarter to $18.1B.

Based on Marshall Wace North America's 13F filing for Q4 2017, filed 14 Feb 2018.